Drug Profile
Celecoxib/diacerein - Zydus Lifesciences
Alternative Names: Diacerein/celecoxib - Zydus LifesciencesLatest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Anthraquinones; Antirheumatics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 22 Jul 2015 No recent reports on development identified - Phase-III for Osteoarthritis in India (PO)